Lupin launches generic TRICOR tablets

20 Nov 2012 Evaluate

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc, has launched its Fenofibrtae tablets, 48 mg and 145 mg strengths in the United States. The company has earlier received final approval for the same from the US Food and Drug Administration (USFDA).

Lupin’s Fenofibrtae tablets are the AB rated generic equivalent of Abbott’s TRICOR tablets and are indicated for primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott’s TRICOR tablets 48 mg and 145 mg had sales of $1.26 billion as per IMS Health, June, 2012.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×